NCT06946797 2026-04-15
CheckMate-1533
Bristol-Myers Squibb
Phase 2 Recruiting
Clinical Trials
64 trialsNCT03899155 2026-04-01
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2 Recruiting
NCT03070392 2026-03-17
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
Phase 2 Completed
NCT05926960 2026-03-09
PORTSIDE
Pfizer
Phase 2 Terminated
NCT05136677 2026-01-23
CheckMate 6DW
Bristol-Myers Squibb
Phase 2 Completed
NCT03993379 2025-12-26
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
CytomX Therapeutics
Phase 2 Terminated
NCT02985957 2025-12-22
CheckMate 650
Bristol-Myers Squibb
Phase 2 Completed
NCT02060188 2025-11-06
CheckMate142
Bristol-Myers Squibb
Phase 2 Completed
NCT03645928 2025-06-19
LN-144
Iovance Biotherapeutics, Inc.
Phase 2 Recruiting
NCT03739710 2025-06-15
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
GlaxoSmithKline
Phase 2 Completed
NCT06790303 2025-06-04
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2
GlaxoSmithKline
Phase 2 Terminated
NCT04382664 2025-01-14
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
Ultimovacs ASA
Phase 2 Completed
NCT05456165 2024-12-31
Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
Gritstone bio, Inc.
Phase 2 Withdrawn
NCT03153085 2024-12-09
A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma
Takara Bio Inc.
Phase 2 Completed
NCT03668119 2024-08-28
CheckMate 848
Bristol-Myers Squibb
Phase 2 Completed
NCT03001882 2024-05-20
CheckMate 592
Bristol-Myers Squibb
Phase 2 Completed
NCT04480502 2024-05-17
ENVASARC
Tracon Pharmaceuticals Inc.
Phase 2 Active not recruiting
NCT04713371 2024-05-09
A Phase 2 Trial for Patients With Metastatic Solid Cancer
Rampart Health, L.L.C.
Phase 2 Active not recruiting
NCT03711188 2024-04-29
A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma
Immodulon Therapeutics Ltd
Phase 2 Completed
NCT05005273 2024-02-28
A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT04894994 2023-12-05
FLX475 in Combination With Ipilimumab in Advanced Melanoma
RAPT Therapeutics, Inc.
Phase 2 Terminated
NCT05284214 2023-09-15
SALIENT
Partner Therapeutics, Inc.
Phase 2 Withdrawn
NCT02935634 2023-06-09
FRACTION-GC
Bristol-Myers Squibb
Phase 2 Completed
NCT02823574 2023-05-03
CheckMate 714
Bristol-Myers Squibb
Phase 2 Completed
NCT02054520 2023-04-18
Immunotherapy Study for Patients With Stage IV Melanoma
Lumos Pharma
Phase 2 Terminated
NCT02659059 2023-04-05
CheckMate 568
Bristol-Myers Squibb
Phase 2 Completed
NCT04088500 2023-01-10
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
Bristol-Myers Squibb
Phase 2 Terminated
NCT02996110 2022-12-19
FRACTION-RCC
Bristol-Myers Squibb
Phase 2 Completed
NCT03430063 2022-11-03
A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer
Regeneron Pharmaceuticals
Phase 2 Terminated
NCT03989362 2022-09-10
EMERGE
Jounce Therapeutics, Inc.
Phase 2 Completed
NCT03130959 2022-08-09
CheckMate 908
Bristol-Myers Squibb
Phase 2 Completed
NCT02644967 2022-08-03
ILLUMINATE-204
Idera Pharmaceuticals, Inc.
Phase 2 Completed
NCT03029780 2022-06-29
CheckMate 800
Bristol-Myers Squibb
Phase 2 Completed
NCT00084656 2022-04-14
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
Bristol-Myers Squibb
Phase 2 Completed
NCT01927419 2022-03-18
CheckMate 069
Bristol-Myers Squibb
Phase 2 Completed
NCT03865082 2022-02-17
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Idera Pharmaceuticals, Inc.
Phase 2 Active not recruiting
NCT04607200 2022-01-11
AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma
Agenus Inc.
Phase 2 Withdrawn
NCT03271047 2022-01-04
Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
Pfizer
Phase 2 Completed
NCT03342417 2021-11-09
Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients
ExcellaBio LLC
Phase 2 Terminated
NCT02320058 2021-10-05
CheckMate204
Bristol-Myers Squibb
Phase 2 Completed
NCT00112580 2021-09-27
MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery
Bristol-Myers Squibb
Phase 2 Completed
NCT01783938 2021-08-13
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
Bristol-Myers Squibb
Phase 2 Completed
NCT02750514 2021-03-22
FRACTION-Lung
Bristol-Myers Squibb
Phase 2 Terminated
NCT04495010 2021-03-19
CheckMate 7UA
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT01611558 2020-07-13
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT02279862 2019-08-28
Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive
Bristol-Myers Squibb
Phase 2 Completed
NCT02272855 2018-09-26
A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Takara Bio Inc.
Phase 2 Completed
NCT01673854 2018-07-24
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Bristol-Myers Squibb
Phase 2 Completed
NCT00527735 2018-07-18
Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)
Bristol-Myers Squibb
Phase 2 Completed
NCT01696045 2017-08-29
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Bristol-Myers Squibb
Phase 2 Terminated